Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA
From Eagle's Eye View: Your Weekly CV Update From ACC.org · · 8 min
This plays from the publisher's own server. We do not host a copy.
Description
In this week's View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the prospective SAMCRO trial which evaluates lifestyle intervention in addition to medical therapy in patients with invasively confirmed angina with no obstructive coronary artery disease (ANOCA).
Subscribe to Eagle's Eye View
Back to Eagle's Eye View: Your Weekly CV Update From ACC.org · Report a problem